Feasibility Study Into the Contraceptive Effect of Estetrol

Pantarhei Bioscience

Status and phase: Completed; Phase 2

Conditions: Healthy

Treatments: Drug: estetrol and progesterone; Drug: estetrol and desogestrel; Drug: estetrol

Study type: Interventional

Funder types: Industry

Identifiers

NCT00563472

PR3081

Details and patient eligibility

About

This is an open study in 50 young, healthy, female volunteers. Women who want to participate and who are using hormonal contraception stop using their hormonal contraceptive and wait for their first spontaneous menstruation (i.e. after a wash-out cycle). Women who do not use hormonal contraception wait for their next menstruation. From the 9th day after start of the menstruation onwards follicle growth will be monitored by ultrasonography until ovulation occurs or until day 24 after start of their menses. Women who ovulate within 24 days after start of their menses will be eligible to participate and will be stratified in one of 4 groups: 10 mg estetrol (E4) alone, 20 mg E4 alone, 20 mg E4 combined with 150 mcg desogestrel and 20 mg E4 combined with 200 mg progesterone. The subjects will be treated for 28 days. Treatment will start on the first day of their menses after the pre-treatment cycle.

During the study period (28 days) the activity of the hypothalamic-pituitary-ovarian (HPO) axis will be investigated by measuring follicular development using ultrasonography and by determining serum concentrations of Follicle Stimulating Hormone (FSH), Luteinising Hormone (LH), estradiol (E2) and Progesterone (P).

Enrollment: 52 patients

Sex: Female

Ages: 18 to 40 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• At least 18 years and not older than 40 years of age
• Willing to use a barrier method of contraception during the wash-out cycle, the pre-treatment cycle, the period of study drug administration, the period of lynestrenol intake (if applicable), and 14 days thereafter or until the follow-up visit if this 14-days period ends before the follow-up visit.
• Women who ovulate in the pre-treatment cycle before or on day 24 (±1) after start of their menses, who have a subsequent P concentration of > 16 nmol/l and whose next menstruation does not start within 6 days after ovulation
• Body Mass Index > 18 and <30 kg/m2
• Good physical and mental health
• Both ovaries visible upon ultrasonography
• Willing to give informed consent in writing

Exclusion criteria

• Clinically significant abnormal results of routine hematology, serum biochemistry, urinanalysis, and/or ECG in the opinion of the Investigator at screening.

• Known or suspected pregnancy

• Lactation

• Pregnancy during accurate hormonal contraceptive use

• Known or suspected breast cancer or a history of breast cancer

• Clinically significant abnormalities of the uterus and/or ovaries detected by examination and/or ultrasound (non-physiological ovarian mass or significant uterine pathology).

• A cervical smear with clinically relevant abnormal cytology within one year before study start.

• Previous use of depot progestogen preparations in the last 6 months.

• Contraindications for contraceptive steroids:

  • a history of, or existing thromboembolic, cardiovascular or cerebrovascular disorder
  • a history of, or existing conditions predisposing to, or being prodromi of, a thrombosis
  • a known defect in the blood coagulation system (e.g. deficiencies in AT-III, protein C, S, and APC resistance)
  • heterozygous for a mutation in coagulation factor II and/or positive for factor V Leiden
  • the presence of a severe or more than one risk factor for vascular disease (e.g. dyslipoproteinaemia; diabetes mellitus; hyperhomocysteinaemia; systemic lupus erythematosus; chronic inflammatory bowel disease; antiphospholipid antibodies; smoking; venous thromboembolism in sibling or parent below the age of 50, or arterial disease in sibling or parent below the age of 35; within 2 weeks after full remobilisation following surgery)
  • hypertension, i.e. systolic blood pressure >140 mmHg and/or diastolic blood pressure >90 mmHg
  • disturbance of liver function: e.g. cholestatic jaundice, a history of jaundice of pregnancy or jaundice due to previous oestrogen use, Rotor syndrome and Dubin-Johnson syndrome
  • known or suspected hormone-dependent tumours or endometrial hyperplasia
  • undiagnosed vaginal bleeding
  • porphyria
  • a history during pregnancy or previous hormone-use of severe pruritus, herpes gestationis or deterioration of otosclerosis

• Use of one or more of the following medications:

  • sex steroids other than the medication of study
  • use at present or within 2 months before start study medication:
  • hydantoins, barbiturates, primidone, carbamazepine, oxcarbazepine, topiramate, troglitazone, felbamate, rifampicin, rifabutin, griseofulvin and St. John's wort (Hypericum perforatum)

• Status post-partum or post-abortion within a period of 2 months before study start

• Administration of investigational drugs within 3 months before start study medication

• A history of (within 12 months) alcohol or drug abuse

• A known hypersensitivity for one of the components of the study medication (eg arachisoil and lactosis)

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

52 participants in 4 patient groups

1

Active Comparator group

Description:

10 mg estetrol

Treatment:

Drug: estetrol

Drug: estetrol

2

Active Comparator group

Description:

20 mg estetrol

Treatment:

Drug: estetrol

Drug: estetrol

3

Active Comparator group

Description:

20 mg estetrol and 150 microg desogestrel

Treatment:

Drug: estetrol and desogestrel

4

Active Comparator group

Description:

20 mg E4 and 200 mg progesterone

Treatment:

Drug: estetrol and progesterone